The Latin America, Middle East and Africa Cardiac Safety Services Market would witness market growth of 13.7% CAGR during the forecast period (2022-2028).
This includes a complete description of incidence, prevalence, and the effect of drug-induced cardiovascular disorders at all stages of drug discovery, development, and post-approval. It also includes finding out how well current non-clinical systems and assays predict the outcome of clinical trials. By focusing on the areas that are the most likely to succeed and where it is not currently possible to foretell clinical outcomes premised on preclinical safety data, one can better understand the mechanistic insights of cardiovascular liabilities.
These are areas like to have the greatest impact on patient health and drug attrition. Giving scientists from all fields more abilities so they can better combine clinical & preclinical data and comprehend the biology and clinical relevance of any changes noticed. This will help assist in discovering and, if possible, eliminating cardiac safety liabilities from molecules, thus helping in building clinically relevant and trustworthy safety biomarkers.
The expansion of the cardiac safety services market is fueled by factors including an increase in the production of new pharmaceuticals, a rise in the number of up-and-coming competitors, and technological advancements that improve consumer demand. Numerous research projects are currently underway, which are expected to give manufacturers a competitive edge as they develop new and inventive cardiac safety services systems. These factors are projected to open up a number of additional chances in the cardiac safety services market.
Coronary heart disease (CHD) is becoming a severe problem in most countries in the Arabian Middle East. For instance, in Iraq, Jordan, and Syria, CHD accounts for the biggest underlying factor of all fatalities. Some of the primary causes of diabetes include obesity, poor diet, hypertension, and a lack of exercise. A major public health problem in the Middle East and Africa is the rise in type 2 diabetes mellitus, with cardiorenal complications (CRCs) being the primary cause of early morbidity and mortality.
The Brazil market dominated the LAMEA Cardiac Safety Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16 Million by 2028. The Argentina market is experiencing a CAGR of 14.3% during (2022-2028). Additionally, The UAE market would display a CAGR of 13.4% during (2022-2028).
Based on Type, the market is segmented into Integrated and Standalone. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies and Contract Research Organizations. Based on Type of Service, the market is segmented into ECG/Holter Measurement, Blood Pressure Measurement, Cardiovascular Imaging, Thorough QT Studies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
This includes a complete description of incidence, prevalence, and the effect of drug-induced cardiovascular disorders at all stages of drug discovery, development, and post-approval. It also includes finding out how well current non-clinical systems and assays predict the outcome of clinical trials. By focusing on the areas that are the most likely to succeed and where it is not currently possible to foretell clinical outcomes premised on preclinical safety data, one can better understand the mechanistic insights of cardiovascular liabilities.
These are areas like to have the greatest impact on patient health and drug attrition. Giving scientists from all fields more abilities so they can better combine clinical & preclinical data and comprehend the biology and clinical relevance of any changes noticed. This will help assist in discovering and, if possible, eliminating cardiac safety liabilities from molecules, thus helping in building clinically relevant and trustworthy safety biomarkers.
The expansion of the cardiac safety services market is fueled by factors including an increase in the production of new pharmaceuticals, a rise in the number of up-and-coming competitors, and technological advancements that improve consumer demand. Numerous research projects are currently underway, which are expected to give manufacturers a competitive edge as they develop new and inventive cardiac safety services systems. These factors are projected to open up a number of additional chances in the cardiac safety services market.
Coronary heart disease (CHD) is becoming a severe problem in most countries in the Arabian Middle East. For instance, in Iraq, Jordan, and Syria, CHD accounts for the biggest underlying factor of all fatalities. Some of the primary causes of diabetes include obesity, poor diet, hypertension, and a lack of exercise. A major public health problem in the Middle East and Africa is the rise in type 2 diabetes mellitus, with cardiorenal complications (CRCs) being the primary cause of early morbidity and mortality.
The Brazil market dominated the LAMEA Cardiac Safety Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16 Million by 2028. The Argentina market is experiencing a CAGR of 14.3% during (2022-2028). Additionally, The UAE market would display a CAGR of 13.4% during (2022-2028).
Based on Type, the market is segmented into Integrated and Standalone. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies and Contract Research Organizations. Based on Type of Service, the market is segmented into ECG/Holter Measurement, Blood Pressure Measurement, Cardiovascular Imaging, Thorough QT Studies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Integrated
- Standalone
By End User
- Pharmaceutical & Biopharmaceutical Companies
- Contract Research Organizations
By Type of Service
- ECG/Holter Measurement
- Blood Pressure Measurement
- Cardiovascular Imaging
- Thorough QT Studies
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Koninklijke Philips N.V.
- Clario
- IQVIA Holdings, Inc.
- Laboratory Corporation of America Holdings
- Pharmaceutical Product Development, Inc.
- SGS S.A.
- Banook Group
- Biotrial Research SAS
- Certara, Inc.
- Celerion
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Cardiac Safety Services Market by Type
Chapter 5. LAMEA Cardiac Safety Services Market by End User
Chapter 6. LAMEA Cardiac Safety Services Market by Type of Service
Chapter 7. LAMEA Cardiac Safety Services Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- Clario
- IQVIA Holdings, Inc.
- Laboratory Corporation of America Holdings
- Pharmaceutical Product Development, Inc.
- SGS S.A.
- Banook Group
- Biotrial Research SAS
- Certara, Inc.
- Celerion
Methodology
LOADING...
